SCHEMBL3606535

SCHEMBL3606535

COc1cc2ncn(-c3cc(O[C@H](C)c4cccc(OCCN5CCN(C)CC5)c4Cl)c(C(=O)O)s3)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 16/20 0.58
PLK3 Q9H4B4 9/20 0.58
IKBKE Q14164 4/20 0.58
CDK2 P24941 2/20 0.58
CYP3A4 P08684 3/20 0.51
CYP2C9 P11712 2/20 0.51
PIM1 P11309 3/20 0.49
NEK2 P51955 3/20 0.49
PIK3CD O00329 2/20 0.49
PDGFRB P09619 2/20 0.49
DAPK3 O43293 2/20 0.49
CSNK2A1 P68400 2/20 0.49
PKN2 Q16513 2/20 0.49
PIK3C2B O00750 1/20 0.49
RIOK3 O14730 1/20 0.49
PIP5K1C O60331 1/20 0.49
RPS6KA4 O75676 1/20 0.49
STK10 O94804 1/20 0.49
PRKD3 O94806 1/20 0.49
KIT P10721 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250740 0.94 PLK1 (0.57) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL4552598 0.94 PLK1 (0.68) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL4347261 0.94 PLK1 (0.68) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL3255925 0.94 PLK1 (0.68) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL3611414 0.91 PLK1 (0.54) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL3605720 0.89 PLK1 (0.64) PLK1PLK3IKBKECDK2PIM1
SCHEMBL13462795 0.86 PLK1 (0.54) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL4552977 0.85 PLK1 (0.53) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL3250892 0.85 PLK1 (0.53) PLK1PLK3IKBKECDK2CYP3A4
SCHEMBL13440245 0.84 PLK1 (0.62) PLK1PLK3IKBKECDK2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100075960-A1 BENZIMIDAZOLE THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2010-03-25 US disclosed
US-7615643-B2 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer SMITHKLINE BEECHAM CORPORATION (US) 2009-11-10 US disclosed
US-20090124615-A9 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2009-05-14 US disclosed
US-20080300247-A1 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124615-A9 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 PLK1 458/4885PLK3 1235/4885IKBKE 1298/4885
US-20080300247-A1 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 PLK1 458/4885PLK3 1235/4885IKBKE 1298/4885
US-20100075960-A1 BENZIMIDAZOLE THIOPHENE COMPOUNDS ABCB1, CYP3A5, CYP3A4 PLK1 450/4885PLK3 1025/4885IKBKE 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.